<DOC>
	<DOC>NCT00795730</DOC>
	<brief_summary>This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease</brief_summary>
	<brief_title>Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria Men or women aged 18 50 years (healthy subjects) or greater than 55 years old (subjects with Alzheimer's Disease) Women must be surgically sterile or postmenopausal Subjects with Alzheimer's Disease must be generally healthy, but may have a stable, chronic illness if well controlled. Exclusion Criteria Healthy subjects may not be on any prescription or investigation drugs within 30 days of start of study. Subjects with Alzheimer's Disease may not be on any cholinesterase inhibitors such as donepezil (Aricept®) or rivastigmine (Exelon®) within 4 weeks of the start of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>schizophrenia</keyword>
</DOC>